Alzheimer; News from the web:

More news on the great trial from Biogen:

A new Alzheimer’s drug that reverses the damage the disease causes in patients’ brains could ‘change the landscape’ of future treatment, according to researchers.

It has already performed so well at early-stage trials involving people living with the disease in the United States that scientists are now in talks aimed at leapfrogging the usual second stage and fast-tracking it for larger trials.

Pharmaceutical firm Biogen, which developed the drug, called aduncanumab, wants to recruit at least 1,000 patients for tests by the end of the year.

Read all about it HERE